The Most Powerful Investment Sector of the Twenty-First Century

Now is the time to invest in Australian biotechnology. AusBiotech believes that biotech has the potential to create unprecedented wealth for its investors, and that the market will soon be flooded with biotechnology products. Biotech pipelines are deep, and there is a large aging population with the need for new and effective drugs. And while the industry is experiencing an increasing swell in talent as well as impressive revenue growth, the Food and Drug Administration’s (FDA) drug approvals keep validating its momentum.

In its 50 years, biotechnology has produced many historical milestones

• 1953 introduction of the double helix
• 1966 the genetic code was cracked
• 1976 the first biotechnology company formed, Genentech
• 1982 the first biotech drug approved by FDA; human Insulin
• 1994 the fist breast cancer gene is discovered
• 2001 the complete sequence of human genome was published
• 2004 the FDA approved the first anti-angiogenic drug for cancer; Avastin

Cancer patients, in particular, are benefiting from recent biotechnology developments. A decade ago there were less than a dozen oncology drugs in clinical trials, most of which were highly toxic chemotherapies. Today there are over 400 targeted biotech medicines, including cancer drugs (with minimal side effects), being tested. With new drugs and treatments popping up everyday, the future surely holds many more cures for patients as well as opportunities for investors.

A Unique Time for Investors

Over the last ten years, developments in biotechnology have been significant and the future holds the potential for many cures and advancements in the medical world.

Biotechnology's impressive discoveries have made it a premier industry, it has

• Produced deep product pipelines
• Demonstrated impressive revenue growth
• Created life-saving drugs and treatments
• Drawn qualified talent to the industry
• Improved the regulatory environment
• Gained strategic alignments with big pharma companies and governments organizations

The trend of increased healthcare spending and technology advancements, and the unmet medical needs for cures and treatments will continue to provide the biotech sector with growth and advancements, as well as lucrative investment opportunities.